World Clinical Nutrition Products Industry

  • January 2015
  • -
  • Global Industry Analysts
  • -
  • 388 pages

This report analyzes the worldwide markets for Clinical Nutrition Products in US$ Million by the following Product Segments: Enteral Nutrition, Infant Nutrition, and Parenteral Nutrition. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 64 companies including many key and niche players such as -

Abbott Nutrition
American HomePatient, Inc.
Baxter International, Inc.
B. Braun Melsungen AG
Claris Lifesciences Ltd.

Table Of Contents

World Clinical Nutrition Products Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
1. Enteral Nutrition I-3
2. Infant Nutrition I-3
3. Parenteral Nutrition I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Bird's Eye View of the Clinical Nutrition Products Market II-1
Emerging Markets: The New Hotspots for Growth II-2
Table 1: GDP Growth for Key Developed and Developing
Countries: 2003-2013 (includes corresponding Graph/Chart) II-3
Infant Nutrition: Rapid Growth in Store II-4
Infant Formula Market: Emerging Markets to Drive Growth II-4
Competitive Landscape II-5
Table 2: Leading Players in the Global Clinical Nutrition
Market (2013): Percentage Breakdown of Value Sales for Abbott
Nutrition, Danone, Fresenius Kabi, Nestle, and Others
(includes corresponding Graph/Chart) II-5

Table 3: Leading Players in the Global Infant Formula Market
(2013): Percentage Share Breakdown of Volume Sales by
Manufacturer (includes corresponding Graph/Chart) II-6
Enteral Nutrition Market II-6
Table 4: Leading Players in the Global Enteral Nutrition
Market (2013): Percentage Breakdown of Value Sales for
Abbott, Nestle, Danone, Fresenius and Others (includes
corresponding Graph/Chart) II-6
Major Players in the Enteral Nutrition and Enteral Infant
Nutrition Market II-7
Parenteral Nutrition Market II-7
Table 5: Leading Players in the Global Parenteral Nutrition
Market (2013): Percentage Share Breakdown of Value Sales for
Baxter International, Fresenius Kabi, B.Braun, Hospira and
Others (includes corresponding Graph/Chart) II-7
Leading Players Operating in the Market for Parenteral
Nutrition II-8
Select Parenteral Nutrition Products by Company II-8

2. MARKET DRIVERS, TRENDS and ISSUES II-10
Impact of Recession in Retrospect and the Road Ahead II-10
Improving Healthcare Expenditure to Drive Demand II-11
Table 6: Per-Capita Healthcare Expenditure in Select Regions
(2013) (includes corresponding Graph/Chart) II-12

Table 7: Healthcare Spending as a Percentage of GDP (2012)
(includes corresponding Graph/Chart) II-13
Aging Population: A Strong Growth Driver II-13
Table 8: Global Population Statistics for the 65+ Age Group
(2013) (includes corresponding Graph/Chart) II-15

Table 9: Elderly Population (60+ Years) as a Percentage of
the Total Population (2012 and 2050) (includes corresponding
Graph/Chart) II-16

Table 10: Life Expectancy at Age 60 and 80 Years -
(2010-2015), (2020-2025) and (2045-2050) (includes
corresponding Graph/Chart) II-17
Rising Incidence of Chronic Diseases to Kindle Market Growth II-17
World Cancer Statistics: Incidence and Mortality Data II-18
Table 11: Worldwide Incidence of Cancer (2013, 2020 and 2030):
Number of New Cases Diagnosed II-19

Table 12: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-19

Table 13: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-20

Table 14: New Cancer Cases in the World by Affected Site
(2012) (In Thousands) (includes corresponding Graph/Chart) II-21

Table 15: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung and
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-21

Table 16: Global Incidence of Common Cancers in Women
(2012): Number of New Cases Reported in Thousands for
Breast, Colorectal, Lung and Bronchus and Liver Cancers
(includes corresponding Graph/Chart) II-22

Table 17: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung and Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-22

Table 18: Global Cancer Mortality in Women for Select
Cancers (2012): Number of Deaths in Thousands for Breast,
Lung and Bronchus, Colorectal and Liver (includes
corresponding Graph/Chart) II-23
Cancer Prone Sites based on Age II-23
Diabetes Mellitus: Another Major Chronic Condition II-23
Table 19: Global Diabetes Mellitus Incidence among Ages
20-79 (2014E and 2035P): Prevalence (in Millions) and
Percentage Share by Geographic Region (includes
corresponding Graph/Chart) II-24

Table 20: Percentage Increase in DM Incidence among Ages
20-79 Worldwide by Geographic Region: 2013-2035 (includes
corresponding Graph/Chart) II-25

Table 21: Countries with Highest Number of People with DM
(in Millions) among Ages 20-79: 2014E and 2035P (includes
corresponding Graph/Chart) II-26

Table 22: Prevalence of Diabetes Mellitus in North America
(2013 and 2035): Number of People with DM (in thousands) in
the 20-79 Age Group for the US, Canada and Mexico (includes
corresponding Graph/Chart) II-27

Table 23: Prevalence of Diabetes Mellitus in Europe (2013 and
2035): Number of People with DM (in thousands) in the 20-79
Age Group for 47 Countries in the Region II-28

Table 24: Prevalence of Diabetes Mellitus in South East Asia
(2013 and 2035): Number of People with DM (in thousands) in
the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives,
Mauritius, Nepal, and Sri Lanka II-29

Table 25: Prevalence of Diabetes Mellitus in Western Asia,
Pacific Regions (2013 and 2035): Number of People with DM (in
thousands) in the 20-79 Age Group for 27 Countries in the
Region II-30

Table 26: Prevalence of Diabetes Mellitus in South and Central
America (2013 and 2035): Number of People with DM (in
thousands) in the 20-79 Age Group for 20 Countries in the
Region II-31

Table 27: Prevalence of Diabetes Mellitus in Africa (2013 and
2035): Number of People with DM (in thousands) in the 20-79
Age Group for 27 Countries in the Region II-32

Table 28: Prevalence of Diabetes Mellitus in Middle East and
North Africa (2013 and 2035): Number of People with DM (in
thousands) in the 20-79 Age Group for 19 Countries in the
Region II-33
Parental Nutrition for Diabetes Patients with Non-functional
Gastrointestinal Tract II-33
Global HIV Statistics II-34
Table 29: Global Prevalence of HIV Infection in 2013 by
Region (in Millions) (includes corresponding Graph/Chart) II-35

Table 30: Newly Infected HIV Population in 2013 by Region
(in Thousands) (includes corresponding Graph/Chart) II-36

Table 31: Global HIV Related Deaths in 2013 by Region (in
Thousands) (includes corresponding Graph/Chart) II-37
Clinical Nutrition in Treatment of Malnutrition: Significant
Growth Opportunities II-37
Non-volitional Nutritional Support Therapy - Vital for
Combating Malnutrition during Hospitalization II-38
Shift towards Home Care Boosts Demand for Clinical Nutrition
Products II-39
Changing Health and Social Care Factors Favor Home Enteral
Feeding II-40
Rising Number of Premature Births Drives Infant Clinical
Nutrition Products Market II-41
Preterm Birth Statistics from WHO II-41
Table 32: Percentage of Preterm Births by Region: 2012)
(includes corresponding Graph/Chart) II-43

Table 33: Top Ten Countries with the Highest Number of
Preterm Births (2012) (includes corresponding Graph/Chart) II-43

Table 34: Top Ten Countries with the Highest Rates of
Preterm Births (per 100 Live Births): 2012 (includes
corresponding Graph/Chart) II-44
Demand for Personalized Medicine to Bode Well for Clinical
Nutrition Products Market II-44
Product Innovations Blur the Lines between Medicine and Foods II-44
Surging Demand for Omega-3 Fatty Acids-Fortified Clinical
Nutrition Products II-45
Advances in Enteral Feeding Devices: Positive Outlook for
Enteral Nutrition Market II-46
Rising Incidence of Pediatric Crohn's Disease Fuels Enteral
Nutrition Market II-47
Specialized Formula Products Inundate the Market II-48
Soy-based Infant Formula Gains Popularity II-48
Pre-mixed IV Solutions: A Step towards Safer Medication Practices II-48
Growing Demand for Low-Cost Parenteral Nutrition Solutions II-49
Rising Preference for Multi-Chamber Bags to Lower Cost of
Parenteral Nutrition Therapy II-49
Increasing Popularity of Intravenous Vitamin C for Cancer
Treatment II-50
Infection Control: A Prime Concern in Parenteral Nutrition II-50
Complacency of Hospitals and Worker/Patient Safety: A Key Issue II-51
Favorable Clinical Findings Strengthens Prospects for Enteral
Nutrition II-51
Rising Preference for Enteral Nutrition - A Threat to
Parenteral Nutrition Market II-51
Advantages and Disadvantages of Enteral Nutrition over
Parenteral Nutrition II-52
Major Challenges Confronting Medical Nutrition Products'
Marketers II-53
Barriers to Widespread Adoption of Clinical Nutrition Products II-54
Reasons for Not Prescribing Clinical Nutrition Products II-54

3. PRODUCT OVERVIEW II-55
Clinical Nutrition: An Introduction II-55
Diseases Indicating Administering of Clinical Nutrition II-55
Advantages of Clinical Nutrition II-56
Classification of Clinical Nutrition Products II-56
Infant Nutrition Products II-57
Table 35: Nutrient Specifications for Infant Formulas (per
100kcal) II-58
List of Infant Nutrition Products II-59
Types of Infant Nutrition Products II-60
Specialized Milk-Based Formulas II-60
Soy-based Infant Formula II-60
Amino Acid-based Formulas II-60
Probiotic Infant Formulas II-60
Prebiotics in Infant Nutrition II-61
Exempt Infant Formulas II-61
Human Milk Oligosaccharides II-62
Nutrition Products for Preterm Infants II-62
Premature Infant Formula II-62
Transitional Formulas II-62
Human Milk Fortifiers II-63
Metabolic Infant Formulas II-63
Follow-up or Follow-on Formulas II-63
Enteral Administration of Infant Formulas in Neonatal
Intensive Care and General Healthcare Settings II-63
Nipple Feeding II-63
Tube Feeding II-64
Enteral Nutrition Products II-64
Table 36: Daily Electrolyte Requirements for Enteral
Nutrition II-65

Table 37: Daily Trace Element Requirement for Enteral
Nutrition II-65

Table 38: Daily Vitamin Requirements for Enteral Nutrition II-66

Table 39: Daily Trace Element Requirements Enteral Nutrition
in Infants II-66

Table 40: Daily Vitamin Requirements for Enteral Nutrition
in Infants II-66
Enteral Nutrition by Age II-67
Enteral Nutrition for Patients aged 21 and older II-67
Enteral Nutrition for Patients below 21 Years II-67
Various Types of Enteral Feeding or Tube Feeding II-67
What Constitutes Enteral Nutrition Diets? II-68
Home-Made Diets II-68
Commercial Enteral Formulas II-68
Elemental Formulas II-68
Oligomeric Formulas II-68
Polymeric Formulas II-69
Special Formulas II-69
Pulmonary Formulas II-69
Liver Formulas II-70
Renal Formulas II-70
Diabetes Formulas II-70
Gastrointestinal Dysfunction Formulas II-70
Immuno-modulatory Formulas II-70
Enteral Nutrition in Patients with Acute Renal Failure (ARF) II-70
Table 41: Nutritional Requirements in Patients with ARF II-71
Enteral Nutrition in Conservatively Treated Patients with
Chronic Renal Failure (CRF) II-71
Table 42: Recommendations for Protein Supply in Adult CRF
Patients (in g/kgBW/day) II-71

Table 43: Mineral Requirements for Patients with CRF II-72
Enteral Nutrition in Haemodialysis Patients II-72
Enteral Nutrition in Chronic Ambulatory Peritoneal Dialysis
(CAPD) Patients II-72
Table 44: Recommendations for Protein and Energy Supply in
Adult Patients on Routine Hemodialysis and CAPD II-72

Table 45: Mineral Requirements of Patients on Haemodialysis
and Chronic Ambulatory Peritoneal Dialysis II-73
Complications of Enteral Feeding II-73
Complications Associated with Enteral Tube Feeding II-73
Parenteral Nutrition II-75
Sources of Parenteral Solutions II-76
Routes of Administration II-76
Types of Parenteral Nutrition Solutions II-77
Total Parenteral Nutrition (TPN) II-77
Table 46: Daily Requirements for Total Parenteral
Nutrition (TPN) in Adults II-77

Table 47: Daily Recommended Parenteral Nutritional Intakes
for Newborns II-78
TPN Formulation II-79
Partial Parenteral Nutrition (PPN) II-79
Home Parenteral Nutrition II-79
Parenteral Nutrition Formulations II-80
Standard Solutions II-80
Three-in-One Standard Bags II-80
Two-in-one Standard Bags II-80
Individual Solutions II-80
Non-Standard Solutions II-81
Classification of Parenteral Nutrition by Type of Nutrients II-81
Amino Acids II-81
Carbohydrates II-81
Lipids II-81
Minerals and Electrolytes II-82
Table 48: Daily Electrolyte Requirements for Parenteral
Nutrition II-82
Micronutrients II-83
Vitamins II-83
Table 49: Daily Vitamin Requirements for Parenteral
Nutrition II-83
Trace Elements II-84
Table 50: Daily Trace Element Requirement for Parenteral
Nutrition II-84
Large and Small Volume Parenteral Solutions II-84
Large Volume Parenteral (LVP) Solutions II-85
Small Volume Parenteral (SVP) Solutions II-85
IV Fat Emulsions - Enabling Maintenance of Bodyweight II-85

4. PRODUCT INNOVATIONS/INTRODUCTIONS/ APPROVALS II-86
Otsuka Introduces HINE E-GEL Concentrated Liquid Nutrition
Product II-86
Alaska Introduces Friso 4 Infant Formula II-86
Fresenius Kabi Obtains FDA Approval for Perikabiven® and Kabiven® II-86
B. Braun Obtains FDA Approval for Nutrilipid® 20% for
Parenteral Nutrition II-86
Ingredion Europe Introduces UNI-PURE IMF 2332 and UNI-PURE IMF
8561 Infant Nutrition Product II-86
Fonterra China to Launch Self-Branded Infant Formula in China II-86
FDA Clears Fresenius Kabi for Emergency Import of
Injectionable TPN Drugs II-87
Marck Biosciences Receives MCC Approval for Six Pharma Products II-87
Restore Health Pharmacy Launches High Quality Nutritional
Supplement II-87
Inergetics Introduces Surgex Ready to Drink Nutritional Beverage II-87
Arla Foods Ingredients Introduces Revolutionary Whey Protein II-87
Nestle Health Science Rolls Out SpikeRight® PLUS for Enteral
Safety II-87
Claris Receives USFDA Approval for Marketing Products in the US II-87

5. RECENT INDUSTRY ACTIVITY II-88
Nestle Sets Up Health Science Manufacturing Plant II-88
Fonterra to Buy Stake in Beingmate II-88
Fonterra Collaborates with Beingmate to Meet Infant Formula
Demand II-88
Baxter Recalls Select Lots of Parenteral Nutrition Products II-88
ITH Pharma Recalls Lipid Phase Parenteral Nutrition Products II-88
Unibrands and ICI to Market and Distribute Morinaga's Infant
Formula in Pakistan II-88
Abbott Receives Approval for ENEVOâ„¢ Liquid for Enteral Use II-88
Nestle to Construct Infant Formula Plant in Mexico II-89
Abbott Inaugurates Nutrition Production Facility in Haiti II-89
Baxter Recalls Select Lots of Premix Parenteral Nutrition
Products II-89
Baxter Collaborates with JW Holdings for Omega 3 Lipids II-89
Mead Johnson Establishes New Manufacturing and Research and
Development Complex II-89
Nestle Health Science Purchases Pamlab II-89
Aspen Acquires IP Rights in Infant Nutritional Businesses of
Nestle II-89
Danone Completes Acquisition of Wockhardt's Nutrition Business II-89
Abbott Nutrition Discontinues Enteral Device Business in the
US and Puerto Rico II-90
Danone Recalls Infant Formula Products in Asia II-90
Yasheng Group Enters Joint Venture with IBC International LLC II-90
Humana Establishes Offices in UAE II-90
FDA Approves Clinolipid Lipid Injectable Emulsion II-90
Nestle Acquires Pfizer Nutrition II-90
Aperture Health Takes Over Triad Therapeutics II-90
B Braun Acquires Nutrichem II-91
Mead Johnson Nutrition Enters into Joint Venture with Sancor II-91
Abbott Plans Collaboration with Syngene for Nutrition RandD Unit II-91
AarhusKarlshamn Expands Capacity to Produce InFatâ„¢ II-91
Abbott to Construct Nutrition Production Facility in Ohio II-91
BioGaia Enters into a Collaboration Agreement with Nestle II-91
Claris Lifesciences Enters into JV with Otsuka Pharma and
Mitsui for Indian Market II-91

6. FOCUS ON SELECT GLOBAL PLAYERS II-92
Abbott Nutrition (US) II-92
American HomePatient, Inc. (US) II-92
Baxter International, Inc. (US) II-92
B. Braun Melsungen AG (Germany) II-93
Claris Lifesciences Ltd. (India) II-94
Groupe Danone (France) II-94
Nutricia North America (US) II-94
Fresenius Kabi AG (Germany) II-95
Hospira, Inc. (US) II-96
Mead Johnson Nutrition Company (US) II-96
Meiji Co., Ltd. (Japan) II-97
Nestle Health Science S.A (Switzerland) II-97
Otsuka Pharmaceutical Factory, Inc. (Japan) II-98
Sino-Swed Pharmaceutical Corp, Ltd. (China) II-99

7. GLOBAL MARKET PERSPECTIVE II-100
Table 51: World Recent Past, Current and Future Analysis for
Clinical Nutrition Products by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Middle East/Africa and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-100

Table 52: World Historic Review for Clinical Nutrition
Products by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Middle East/Africa and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) II-101

Table 53: World 14-Year Perspective for Clinical Nutrition
Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle
East/Africa and Latin America Markets for Years 2007, 2015 and
2020 (includes corresponding Graph/Chart) II-102

Table 54: World Recent Past, Current and Future Analysis for
Enteral Nutrition Products by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Middle East/Africa and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-103

Table 55: World Historic Review for Enteral Nutrition Products
by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Middle East/Africa and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) II-104

Table 56: World 14-Year Perspective for Enteral Nutrition
Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle
East/Africa and Latin America Markets for Years 2007, 2015 and
2020 (includes corresponding Graph/Chart) II-105

Table 57: World Recent Past, Current and Future Analysis for
Infant Nutrition Products by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Middle East/Africa and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-106

Table 58: World Historic Review for Infant Nutrition Products
by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Middle East/Africa and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) II-107

Table 59: World 14-Year Perspective for Infant Nutrition
Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle
East/Africa and Latin America Markets for Years 2007, 2015 and
2020 (includes corresponding Graph/Chart) II-108

Table 60: World Recent Past, Current and Future Analysis for
Parenteral Nutrition Products by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Middle East/Africa and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-109

Table 61: World Historic Review for Parenteral Nutrition
Products by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Middle East/Africa and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) II-110

Table 62: World 14-Year Perspective for Parenteral Nutrition
Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle
East/Africa and Latin America Markets for Years 2007, 2015 and
2020 (includes corresponding Graph/Chart) II-111


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Market Overview III-1
Rapidly Aging Demographics: A Major Driving Factor III-1
Table 63: North American Elderly Population by Age Group
(1975-2050) (includes corresponding Graph/Chart) III-2
Rising Incidences of Chronic Diseases Enhance Need for
Clinical Nutrition Products III-3
Cancer Statistics in the US III-3
Table 64: New Cancer Cases in US by State: 2014 III-4

Table 65: New Cancer Cases in the US by Gender and
Affected Site: 2014 III-5

Table 66: Cancer Related Deaths in the US by Gender and
Body Site: 2014 III-7
Prevalence of Diabetes Mellitus in North America III-8
Table 67: Prevalence of Diabetes Mellitus in North America
(2013 and 2035): Number of People with DM (in thousands) in
the 20-79 Age Group for the US, Canada and Mexico
(includes corresponding Graph/Chart) III-9

Table 68: North America Incidence of Type 1 Diabetes in
Children (2012) (includes corresponding Graph/Chart) III-10
An Insight into Infant Nutrition Market III-10
Table 69: Baby and Toddler Nutrition Market in the US (2013):
Percentage Share Breakdown of Value Sales by Segment
(includes corresponding Graph/Chart) III-10
Rising Number of Premature Births Augurs Well for Market
Growth III-11
Table 70: US Pre-term Birth Statistics (2012) III-11
Strategic Innovations to Buoy Consumer Demand III-12
Human Breast Milk-Like Infant Formulas to Gain Popularity III-12
Competition III-13
Table 71: Leading Players in the US Infant Formula Market
(2013): Percentage Share Breakdown of Value Sales for
Abbott, Mead Johnson, Nestle, and Others (includes
corresponding Graph/Chart) III-13

Table 72: Leading Infant Formula (Powder) Manufacturers in
the US (2012): Percentage Share Breakdown of Value Sales*
for Mead Johnson Nutrition Co, Abbott Nutrition, Nestle
Healthcare Nutrition, Gerber Products Co, Private Label
and Others (includes corresponding Graph/Chart) III-13

Table 73: Leading Infant Formula Brands in the US (2012):
Percentage Share Breakdown of Value Sales* for Enfamil
Premium, Similac Advance, Similac Sensitive, Enfamil
Gentlease, Gerber Good Start Gentle Plus, Gerber Good
Start Gentle, Similac Advance Early Shield, Private label
and Others (includes corresponding Graph/Chart) III-14
WIC Contract and the Infant Formula Rebate Program III-14
WIC's Infant Formula Rebate Program III-15
Enteral Nutrition Market III-15
Home Healthcare Fuels Demand for Home Enteral Nutrition
Products III-16
Enteral Nutrition Therapy to Treat Adult Malnutrition:
Opportunities for Growth III-17
Reimbursement Scenario for Enteral Nutrition Therapy III-17
ENT Coverage under Part A III-17
ENT Coverage under Part B III-18
Reimbursements for Enteral Nutrients III-19
Parenteral Nutrition Market: An Overview III-19
Medicare Coverage for Parenteral Nutrition Therapy III-19
Reimbursement Regulations to Hamper Market Growth III-20
Shift towards Enteral Nutrition Therapies - A Threat to
Parenteral Nutrition Market III-21
Advantages and Disadvantages of Enteral Nutrition over
Parenteral Nutrition III-21
A.S.P.E.N. Practice Guidelines for Parenteral Nutrition III-21
A.S.P.E.N. Guidelines for Parenteral Nutrition (as of 2004) III-22
Impact of Patient Protection and Affordable Care Act on IV
Solutions Market III-23
Product Launches III-24
Strategic Corporate Developments III-25
Key Players III-26
B.Market Analytics III-30
Table 74: US Recent Past, Current and Future Analysis for
Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-30

Table 75: US Historic Review for Clinical Nutrition Products
by Product Type - Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-31

Table 76: US 14-Year Perspective for Clinical Nutrition
Products by Product Type - Percentage Breakdown of Dollar
Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-32

2. CANADA III-33
A.Market Analysis III-33
Outlook III-33
Rising Incidence of Chronic Diseases: A Major Growth Driver III-33
Table 77: New Cancer Cases in Canada by Gender and Affected
Site: 2014 III-34

Table 78: New Cancer Cases in Canada by Province: 2014
(includes corresponding Graph/Chart) III-35

Table 79: New Cancer Cases in Canada by Age Group: 2014
(includes corresponding Graph/Chart) III-36

Table 80: Cancer Related Deaths in Canada by Gender and
Affected Site: 2014 (includes corresponding Graph/Chart) III-37

Table 81: Cancer Related Deaths in Canada by Province: 2014
(includes corresponding Graph/Chart) III-38

Table 82: Cancer Related Deaths in Canada by Age Group:
2014 (includes corresponding Graph/Chart) III-39

Table 83: Adult Diabetes Population by Age Group in Canada
(2013) (In ‘000s) (includes corresponding Graph/Chart) III-39
B.Market Analytics III-40
Table 84: Canadian Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-40

Table 85: Canadian Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-41

Table 86: Canadian 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-42

3. JAPAN III-43
A.Market Analysis III-43
Outlook III-43
Rising Incidence of Chronic Diseases - A Prime Growth Driver III-43
Table 87: Cancer Related Deaths by Age Groups: 2013 III-44

Table 88: Prevalence of Diabetes Mellitus in Japan (2013 and
2035) (includes corresponding Graph/Chart) III-44
Product Launch III-45
Strategic Corporate Developments III-45
Key Players III-45
B.Market Analytics III-47
Table 89: Japanese Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-47

Table 90: Japanese Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-48

Table 91: Japanese 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-49

4. EUROPE III-50
A.Market Analysis III-50
Outlook III-50
Debt Crisis in Europe Affects Healthcare Industry III-50
Aging Population and Rising Incidence of Chronic Diseases to
Drive Growth III-51
Aging Statistics III-52
Table 92: Population Breakup by Age Group for Select
European Countries: 2012 (as a Percentage of Total
Population) (includes corresponding Graph/Chart) III-52
Cancer Trends III-52
Table 93: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-53
Prevalence of Diabetes Mellitus in Europe III-54
Table 94: Prevalence of Diabetes Mellitus in Europe (2013 and
2035): Number of People with DM (in thousands) in the
20-79 Age Group for 47 Countries in the Region III-54
An Overview of Enteral Feeding Market in Europe III-55
Prospering Enteral Nutrition Market: New Avenues for
Ingredient Suppliers III-55
Surging Interest in Home Healthcare: Gains for Enteral
Nutrition Market III-56
Infant Nutrition Market III-56
Market Overview III-56
The EC Directive on Infant Formulae and Follow-on Formulae III-56
FSA's Control on Infant Formulas and Follow-on Formula
Advertisements III-58
B.Market Analytics III-59
Table 95: European Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-59

Table 96: European Historic Review for Clinical Nutrition
Products by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-60

Table 97: European 14-Year Perspective for Clinical
Nutrition Products by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-61

Table 98: European Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-62

Table 99: European Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-63

Table 100: European 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-64

4a. FRANCE III-65
A.Market Analysis III-65
Outlook III-65
An Insight into the Market for Enteral Nutrition III-65
Corporate Development III-66
Groupe Danone - A Key Player III-66
B.Market Analytics III-67
Table 101: French Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-67

Table 102: French Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-68

Table 103: French 14-Year Perspective for Clinical Nutrition
Products by Product Type - Percentage Breakdown of Dollar
Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-69

4b. GERMANY III-70
A.Market Analysis III-70
Outlook III-70
Entering Nutrition Market in Germany - An Overview III-70
Strategic Corporate Developments III-70
Key Players III-71
B.Market Analytics III-72
Table 104: German Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-72

Table 105: German Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-73

Table 106: German 14-Year Perspective for Clinical Nutrition
Products by Product Type - Percentage Breakdown of Dollar
Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-74

4c. ITALY III-75
Market Analysis III-75
Table 107: Italian Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-75

Table 108: Italian Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-76

Table 109: Italian 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-77

4d. THE UNITED KINGDOM III-78
A.Market Analysis III-78
Outlook III-78
Corporate Development III-78
B.Market Analytics III-79
Table 110: UK Recent Past, Current and Future Analysis for
Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-79

Table 111: UK Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-80

Table 112: UK 14-Year Perspective for Clinical Nutrition
Products by Product Type - Percentage Breakdown of Dollar
Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-81

4e. SPAIN III-82
Market Analysis III-82
Table 113: Spanish Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-82

Table 114: Spanish Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-83

Table 115: Spanish 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-84

4f. RUSSIA III-85
Market Analysis III-85
Table 116: Russian Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-85

Table 117: Russian Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant
Nutrition, and Parenteral Nutrition Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2013 (includes corresponding Graph/Chart) III-86

Table 118: Russian 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-87

4g. REST OF EUROPE III-88
A.Market Analysis III-88
Outlook III-88
Product Launches III-88
Strategic Corporate Developments III-88
Nestle Health Science S.A (Switzerland) - A Key Player III-89
B.Market Analytics III-90
Table 119: Rest of Europe Recent Past, Current and Future
Analysis for Clinical Nutrition Products by Product Type -
Enteral Nutrition, Infant Nutrition, and Parenteral
Nutrition Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-90

Table 120: Rest of Europe Historic Review for Clinical
Nutrition Products by Product Type - Enteral Nutrition,
Infant Nutrition, and Parenteral Nutrition Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) III-91

Table 121: Rest of Europe 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-92

5. ASIA-PACIFIC III-93
A.Market Analysis III-93
Outlook III-93
Rising Diabetes Mellitus Cases in Asia-Pacific - Opportunity
for Clinical Nutrition Companies III-93
Table 122: Prevalence of Diabetes Mellitus in South East
Asia (2013 and 2035): Number of People with DM (in thousands)
in the 20-79 Age Group for Bangladesh, Bhutan, India,
Maldives, Mauritius, Nepal, and Sri Lanka III-93

Table 123: Prevalence of Diabetes Mellitus in Western Asia,
Pacific Regions (2013 and 2035): Number of People with DM (in
thousands) in the 20-79 Age Group for 27 Countries in the
Region III-94
B.Market Analytics III-95
Table 124: Asia-Pacific Recent Past, Current and Future
Analysis for Clinical Nutrition Products by Geographic
Region - China, India and Rest of Asia-Pacific Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-95

Table 125: Asia-Pacific Historic Review for Clinical
Nutrition Products by Geographic Region - China, India and
Rest of Asia-Pacific Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-96

Table 126: Asia-Pacific 14-Year Perspective for Clinical
Nutrition Products by Geographic Region - Percentage
Breakdown of Dollar Sales for China, India and Rest of
Asia-Pacific Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) III-97

Table 127: Asia-Pacific Recent Past, Current and Future
Analysis for Clinical Nutrition Products by Product Type -
Enteral Nutrition, Infant Nutrition, and Parenteral
Nutrition Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2014 through 2020 III-98

Table 128: Asia-Pacific Historic Review for Clinical
Nutrition Products by Product Type - Enteral Nutrition,
Infant Nutrition, and Parenteral Nutrition Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2013 (includes corresponding
Graph/Chart) III-99

Table 129: Asia-Pacific 14-Year Perspective for Clinical
Nutrition Products by Product Type - Percentage Breakdown of
Dollar Sales for Enteral Nutrition, Infant Nutrition, and
Parenteral Nutrition Markets for Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-100

5a. CHINA III-101
A.Market Analysis III-101
Outlook III-101
Infant Formula Market: A Review III-101
Table 130: Infant Formula Market in China (2013):
Percentage Share Breakdown of Value Sales by Price Category
(includes corresponding Graph/Chart) III-101
Consolidation to Strengthen Infant Formula Industry III-102
China Slaps Fines on Six Infant Formula Companies for
Price-Fixing III-102
Companies Lower Prices of Infant Formula Following Anti-
Monopoly Probe III-102
Key Challenges Facing Infant Formula Market III-103
Rising Competition from Imported Products III-103
Birth Rate III-103
Need to Regain Consumer Confidence III-103
Others III-103
Competition III-103
Table 131: Leading Players in the Chinese Infant Formula
Market (2013): Percentage Share Breakdown of Value Sales
for Abbott, Beingmate, Biostime, Danone, Daqing Dairy,
Mead Johnson, Nestle, Yashili, and Others (includes
corresponding Graph/Chart) III-104
Parenteral Nutrition Market: An Insight III-104
Enteral Nutrition Preparations Market: Competitive Landscape III-104
Table 132: Leading Suppliers of Enteral Nutrition
Preparations in China (2012): Percentage Share Breakdown of
Value Sales for NUTRICIA (China), Sino-Swed Pharmaceutical
Corp. Ltd, Novartis, Xi`an LIBANG Pharmaceutical Co, Ltd
and Others (includes corresponding Graph/Chart) III-104
Strategic Corporate Developments III-105
Key Player III-105
B.Market Analytics III-106
Table 133: Chinese Recent Past, Current and Future Analysis
for Clinical Nutrition Products by Product Type - Enteral
Nutrition, Infant Nutrition, and Parenteral Nutrition
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-106

Table 134: Chinese Historic Review for Clinical Nutrition
Products by Product Type - Enteral Nutrition, Infant

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ...

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • November 2014
  • by Global Data

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the ...

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.